How Chronic Stress Hormones Accelerate Every Major Hallmark of Aging
A landmark review reveals how sustained glucocorticoid exposure drives aging biology — and what can be done about it.
Summary
Glucocorticoids are stress hormones that, in short bursts, help the body adapt. But when chronically elevated — from ongoing psychological stress, poor sleep, obesity, inflammation, or long-term steroid medications — they appear to accelerate biological aging across multiple systems. This review from top researchers including Carlos López-Otín and Guido Kroemer maps how chronic glucocorticoid signaling disrupts nutrient sensing, suppresses autophagy, impairs mitochondrial function, and promotes cellular senescence. A key player is a protein called ACBP/DBI, which blocks the cellular cleanup process of autophagy and worsens metabolic and immune aging. The clinical consequences include earlier onset of metabolic syndrome, osteoporosis, muscle loss, neurodegeneration, heart disease, immune decline, and cancer. The authors also discuss potential strategies to counteract these effects.
Detailed Summary
Stress is often described as an accelerant of aging, but the precise biological mechanisms linking the two have remained incompletely mapped. This review, published in Cell Metabolism by a team of leading aging researchers including Carlos López-Otín and Guido Kroemer, provides a comprehensive framework for understanding how chronic glucocorticoid (GC) signaling drives accelerated biological aging.
Glucocorticoids are steroid hormones produced by the adrenal glands in response to stress, inflammation, and circadian cues. In acute settings, they are adaptive and essential. The problem arises with sustained elevation — a state increasingly common due to psychosocial stress, circadian disruption, obesity, chronic inflammation, steroid medications, or cancer. Under these conditions, GC signaling transitions from protective to harmful.
The review systematically maps how chronic GC exposure intersects with established hallmarks of aging: it dysregulates nutrient-sensing pathways, suppresses macroautophagy (the cellular recycling system), impairs mitochondrial quality control, and promotes cellular senescence — the accumulation of dysfunctional cells that drive tissue deterioration. A central mechanistic actor is ACBP/DBI, a GC-responsive protein that inhibits autophagy and amplifies downstream metabolic and immune consequences of GC excess.
Clinically, these mechanisms translate into earlier and more severe age-related diseases. Patients with chronic GC elevation — whether endogenous or iatrogenic — show accelerated risk for metabolic syndrome, osteoporosis, sarcopenia, cardiovascular disease, neurodegeneration, immunosenescence, and cancer. This has direct relevance for the millions of patients prescribed long-term corticosteroids and for individuals under chronic psychological or physiological stress.
The authors also discuss potential mitigation strategies, though specific interventions are not detailed in the abstract. Caveats include that this is a narrative review, and several authors hold significant commercial conflicts of interest in the therapeutic targeting of ACBP/DBI. The full text was not available for detailed assessment.
Key Findings
- Chronic glucocorticoid elevation — from stress, obesity, or steroids — accelerates multiple hallmarks of biological aging.
- GC excess suppresses autophagy, impairs mitochondrial quality control, and promotes cellular senescence.
- The protein ACBP/DBI acts as a key mediator, amplifying the pro-aging metabolic and immune effects of sustained GC signaling.
- Chronic GC elevation is clinically linked to earlier onset of sarcopenia, osteoporosis, neurodegeneration, and cardiovascular disease.
- Therapeutic targeting of ACBP/DBI is proposed as a strategy to counteract GC-driven aging phenotypes.
Methodology
This is a narrative review article, not a primary research study. The authors synthesize existing mechanistic and clinical evidence linking chronic glucocorticoid signaling to aging biology. Specific search criteria, inclusion/exclusion rules, or meta-analytic methods are not described in the abstract.
Study Limitations
This summary is based on the abstract only, as the full text was not available. As a narrative review, it does not provide systematic evidence grading or quantitative effect sizes. Several authors hold patents and financial interests in ACBP/DBI-targeting therapeutics, representing a potential conflict of interest that warrants consideration.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.